Evaluation of Pulmonary Toxicities in Lymphoma Patients Receiving Brentuximab Vedotin

Tiffany Guan(University of California San Francisco Medical Center), Bita Fakhri(University of California, San Francisco), Haifaa Abdulhaq(University of California, San Francisco), Rebecca Young(University of California San Francisco Medical Center), Hanson Mouanoutoua(University of California, San Francisco), Mimi Lo(University of California, San Francisco), Fouad Boulbol(Community Medical Center), Raymond Chu(University of California, San Francisco), Weiyun Z. Ai(City College of San Francisco)
Blood
November 5, 2021
10.1182/blood-2021-151420
Cited by 1

Related Papers

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|683
In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
|Journal of Clinical Oncology|2010|487
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
|The Lancet|2021|456
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
|The Lancet Oncology|2021|428
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
|Blood|2012|396